(e)(2) of section 713 shall apply with respect to the cov-
erage required by subsection (a) in the same manner as 
they apply with respect to the coverage required under 
such section, except that January 1, 2012, shall be sub-
stituted for the date referred to in subsection (b)(3) of 
such section. 
‘‘(e) CONSTRUCTION.—Nothing in this section shall 
be construed— 
‘‘(1) to require the use of orally administered 
anticancer medications as a replacement for other 
anticancer medications; or 
‘‘(2) to prohibit a group health plan or health 
insurance issuer from requiring prior authorization 
or imposing other appropriate utilization controls in 
approving coverage for any chemotherapy.’’. 
(2) Section 731(c) of such Act (29 U.S.C. 1191(c)) 
is amended by striking ‘‘section 711’’ and inserting ‘‘sec-
tions 711 and 716’’. 
(3) Section 732(a) of such Act (29 U.S.C. 1191a(a)) 
is amended by striking ‘‘section 711’’ and inserting ‘‘sec-
tions 711 and 716’’. 
(4) The table of contents in section 1 of such Act 
is amended by inserting after the item relating to section 
714 the following new items: 
‘‘Sec. 715. Additional market reforms. 
‘‘Sec. 716. Parity in coverage for oral anticancer drugs.’’. 
VerDate Mar 15 2010 
03:30 Aug 03, 2011
Jkt 099200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6211
E:\BILLS\H2746.IH
H2746
jbell on DSKDVH8Z91PROD with BILLS
(b) PUBLIC HEALTH SERVICE ACT AMENDMENTS.— 
(1) Title XXVII of the Public Health Service Act is 
amended by inserting after section 2728 (42 U.S.C. 
300gg–28), as redesignated by section 1001(2) of the Pa-
tient Protection and Affordable Care Act (Public Law 
111–148), the following new section: 
‘‘SEC. 2729. PARITY IN COVERAGE FOR ORAL ANTICANCER 
DRUGS. 
‘‘(a) IN GENERAL.—Subject to subsection (b), a 
group health plan, and a health insurance issuer offering 
group or individual health insurance coverage, that pro-
vides benefits with respect to intravenously administered 
or injected anticancer medications shall provide for no less 
favorable coverage for prescribed, orally administered 
anticancer medication that is used to kill or slow the 
growth of cancerous cells and that has been approved by 
the Food and Drug Administration. 
‘‘(b) LIMITATION.—Subsection (a) shall only apply to 
anticancer medication that is prescribed based on a find-
ing by the treating physician that the medication— 
‘‘(1) is medically necessary for the purpose of 
killing or slowing the growth of cancerous cells in a 
manner that is in accordance with nationally accept-
ed standards of medical practice; 
VerDate Mar 15 2010 
03:30 Aug 03, 2011
Jkt 099200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H2746.IH
H2746
jbell on DSKDVH8Z91PROD with BILLS
‘‘(2) is clinically appropriate in terms of type, 
frequency, extent site, and duration; and 
‘‘(3) is not primarily for the convenience of the 
patient, physician, or other health care provider. 
‘‘(c) APPLICATION OF COST-SHARING AND RESTRIC-
TIONS.— 
‘‘(1) IN GENERAL.—The coverage of anticancer 
medication under subsection (a) may be subject to 
annual deductibles and coinsurance or copayments 
so long as such deductibles, coinsurance, and copay-
ments do not exceed the deductibles, coinsurance, 
and copayments that are applicable to intravenously 
administered or injected anticancer medications 
under the plan or coverage for the same purpose. 
‘‘(2) RESTRICTION.—A group health plan or 
health insurance issuer may not, in order to comply 
with the requirement of subsection (a)— 
‘‘(A) impose an increase in out-of-pocket 
costs with respect to anticancer medications; or 
‘‘(B) reclassify benefits with respect to 
anticancer medications. 
‘‘(d) APPLICATION
OF
NOTICE, PROHIBITIONS, 
ETC.—The provisions of subsections (b), (c), (d), and 
(e)(2) of section 713 of the Employee Retirement and In-
come Security Act of 1974 shall apply with respect to the 
VerDate Mar 15 2010 
03:30 Aug 03, 2011
Jkt 099200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H2746.IH
H2746
jbell on DSKDVH8Z91PROD with BILLS
coverage required by subsection (a) in the same manner 
as they apply with respect to the coverage required under 
such section, except that January 1, 2012, shall be sub-
stituted for the date referred to in subsection (b)(3) of 
such section. 
‘‘(e) CONSTRUCTION.—Nothing in this section shall 
be construed— 
‘‘(1) to require the use of orally administered 
anticancer medications as a replacement for other 
anticancer medications; or 
‘‘(2) to prohibit a group health plan or health 
insurance issuer from requiring prior authorization 
or imposing other appropriate utilization controls in 
approving coverage for any chemotherapy.’’. 
(2) Section 2724(c) of such Act (42 U.S.C. 300gg– 
23(c)), as redesignated by section 1001(4) and subsection 
(c)(14) of the section 1563 (relating to conforming amend-
ments) of Public Law 111–148, is amended by striking 
‘‘section 2704’’ and inserting ‘‘sections 2725 and 2729’’. 
(3) Section 2762(b)(2) of such Act (42 U.S.C. 
300gg–62(b)(2)) is amended by striking ‘‘section 2751’’ 
and inserting ‘‘sections 2751 and 2729’’. 
(4) For purposes of applying section 2729 of the 
Public Health Service Act, as inserted by paragraph (1), 
to individual health insurance coverage before 2014, the 
VerDate Mar 15 2010 
03:30 Aug 03, 2011
Jkt 099200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H2746.IH
H2746
jbell on DSKDVH8Z91PROD with BILLS